Skip to Main Content

View Public Comments for Aprepitant for Chemotherapy-Induced Emesis

Use the browser below to select the Comment Period for which you would like to view the comments for the selected document. You can use the alphabetical links above the results table to jump to comments submitted by a commenter whose last name starts with that letter. Select the ‘Expand All Comments’ link to view all the full comments, and click the ‘Collapse All Comments’ link to view only the abstract for all comments. Select the ‘More’ link in the Comment to view the full text of the specific comment in a new window.
The first (earliest) set of comments are displayed by default in the Public Comment Results section. To view additional Comment Periods, use the radio button options and select the "Submit" button.
An asterisk (*) indicates a required field.

      Select one period.




[53 Comments]
Page 1 of 3
FirstPrev123NextLast
First character of titleCommenterComment Information
A
Adams, Pharm.D., Jonathan Title: Chief of Pharmacy Services & Assistant Vice Pres.
Organization: Roswell Park Cancer Institute
Date: 10/31/2012
Comment:

I encourage CMS to add moderately-emetogenic chemotherapy regimens to the National Coverage Determination for aprepitant. The use of oral aprepitant with moderately-emetogenic chemotherapy (MEC) in combination with dexamethasone and a 5-HT3 More opens in new window

A
Allen, Steven Title: Chair, Committee on Practice
Organization: American Society of Hematology
Date: 10/31/2012
Comment:

October 31, 2012

Louis Jacques, M.D.
Director
Coverage and Analysis Group Office of Clinical Standards & Quality (OCSQ)
Centers for Medicare and Medicaid Services (CMS)
7500 Security More opens in new window

A
Almosa, Josryl Date: 10/19/2012
Comment:
Please add oral Emend (aprepitant) to the list of covered meds under Medicare Part B. This medication has a unique mechanism of action that would provide our patients who are on highly emetogenic chemotherapy regimens nausea relief so that they More opens in new window
B
Bartel, Sylvia Title: VP Pharmacy
Organization: Dana-Farber Cancer Institute
Date: 10/31/2012
Comment:

October 31, 2012

Louis Jacques, MD
Director, Coverage and Analysis Group (OCSQ)
Centers for Medicare & Medicaid Services (CMS)
7500 Security Boulevard
Baltimore, MD 21244-1850

RE: Comments on the More opens in new window

B
Berger, PharmD, BCOP, Michael Title: Specialty Practice Pharmacist
Organization: The James Cancer Hospital at The Ohio State University
Date: 10/24/2012
Comment:

I encourage CMS to add moderately-emetogenic chemotherapy regimens to the NCD for oral aprepitant. The use of oral aprepitant with MEC in combination with (oral formulations only) dexamethasone and a 5-HT3 antagonist is effective in preventing More opens in new window

B
Blouin, Gayle Title: Clinical Lead Ambulatory Oncology
Organization: Massachusetts General Hospital
Date: 10/03/2012
Comment:

The restricted coverage of aprepitant has been a hardship for many cancer patients, especially our seniors. Many chemotherapy agents, classified as moderately-emetogenic (MEC), have the potential to be highly-emetogenic, and use of aprepitant is More opens in new window

B
Bocchino, Carmella Title: EVP, Clinical Affairs and Strategic Planning
Organization: America's Health Insurance Plans (AHIP)
Date: 10/31/2012
Comment:
Cheryl Gilbreath, PharmD, MBA, R.Ph
Lead Analyst
Centers for Medicare and Medicaid Services
Mail Stop C1-09-06
7500 Security Boulevard
Baltimore, Maryland 21244-1850

Dear Dr. More opens in new window

B
Burken, Mitchell Title: Contractor Medical Director
Organization: Novitas Solutions, Inc.
Date: 10/04/2012
Comment:

The Tracking Sheet only refers to oral Aprepitant. However, since there have been Medicare Administrative Contractor (MAC) issues regarding IV dosing as an alternative for beneficiaries with oral anti-emetic failures, I would strongly recommend More opens in new window

C
Callahan, Michael Date: 10/24/2012
Comment:
I encourage CMS to add moderately-emetogenic chemotherapy regimens to the National Coverage Determination for aprepitant. The use of oral aprepitant with moderately-emetogenic chemotherapy (MEC) in combination with (oral formulations only) More opens in new window
C
campen, christopher Title: PharmD BCPS
Organization: UAHN
Date: 10/29/2012
Comment:
I encourage CMS to add moderately-emetogenic chemotherapy regimens to the National Coverage Determination for aprepitant. The use of oral aprepitant with moderately-emetogenic chemotherapy (MEC) in combination with dexamethasone and a 5-HT3 More opens in new window
C
Christen, Catherine Title: Clinical Pharmacist
Organization: University of Michigan
Date: 10/19/2012
Comment:
Many moderately emetogenic chemotherapy agents can cause significant delayed nausea, especially when combined together. Nausea is often not controlled with non-aprepitant containing anti-emetic regimens, resulting in patients paying out of pocket More opens in new window
C
Crawford, Brooke Title: Pharmacy Coordinator of Clinical/Research Services
Organization: The Arthur G. James Cancer Hospital
Date: 10/31/2012
Comment:

The initial aprepitant NCD became effective in 2005 and since that time the Food and Drug Administration has expanded aprepitant’s approved indications to include moderately emetogenic anticancer (MEC)chemotherapy agents. Additionally, the More opens in new window

C
Cross, Shane Date: 10/19/2012
Comment:
I would like to voice my support for approving coverage of oral aprepiant to prevent chemotherapy-induced emesis in patients receiving moderately emetogenic chemotherapy. Of course aprepitant would be given in combination with other antiemetics as More opens in new window
D
Driver, Paul Title: Pharmacy Clinical Coordinotor (PharmD BCPS)
Organization: St Joseph Reg Med Ctr
Date: 10/08/2012
Comment:
Aprepitant in a valualbe addition to supportive care in highly emetogenic chemotherapy management. Its availability for oral and intravenous management of these pateints is critical to maintaining the dose intensity needed to treat this patient More opens in new window
E
Egerton, Nancy Title: Manager of Pharmacy Services
Organization: New York Oncology Hematology
Date: 10/19/2012
Comment:
I am in full support of the proposal to amend the current coverage of antiemtic drugs related to the administraiton of moderate and highly emetogenic chemotherapy regimens. Our patients face a difficult struggle in their plight against cancer. We More opens in new window
E
England, Tina Date: 10/22/2012
Comment:
Not all patients will have the same experience when faced with side effects of nausea and vomiting. There are many factors that may increase the risk of having CINV (chemotherapy induced nausea and vomiting) outside of the emetic potential of the More opens in new window
F
Fishman, Marc Title: Medical Director and CEO
Organization: Oncology Analytics
Date: 10/08/2012
Comment:

October 8, 2012

We read with interest NCCN’s request to CMS that CMS provide coverage for oral aprepitant in combination with a 5HT3 antagonist and dexamethasone for moderately emetogenic anticancer chemotherapy (MEC).

We More opens in new window

F
Fishman, MD, Marc Title: Medical Director and CEO
Organization: Oncology Analytics, Inc.
Date: 10/24/2012
Comment:

We vigorously disagree with the addition of palonosetron to the current NCD list of acceptable 5-HT3 antagonists for use with aprepitant and dexamethasone in moderately emetogenic anticancer chemotherapy (MEC) due to a complete lack of level 1 More opens in new window

F
Flynn, Kimberly Date: 10/22/2012
Comment:
Since CMS developed the aprepitant National Coverage Determination (NCD), the emetogenic potential ratings of cancer chemotherapy medications have been updated, adding new anticancer medications and standards of care for patients undergoing More opens in new window
F
Frankel, Marvin Title: Pharmacy Manager
Organization: Hematology Oncology Assoc of Brooklyn
Date: 10/22/2012
Comment:
Many patients receiving chemo regimens with moderately emetogenic agents such as carboplatin, oxaliplatin and irinotecan experience CINV. Many of these patients are metastatic colon, lung and ovarian cancer patients on long term treatment. Being More opens in new window
G
Grafton, Charlene H. Organization: www.charlenehgrafton.com
Date: 10/01/2012
Comment:

DMSO has sulfa (sulfite), so, ergo, if you are allergic to sulfa, you cannot use with Cisplatin [PHI Redacted]

Charlene H. Grafton
Nurse Case Mgr. and More opens in new window
G
Griffith, Niesha Date: 10/31/2012
Comment:

I encourage CMS to add moderately-emetogenic chemotherapy regimens to the NCD for oral aprepitant. The use of oral aprepitant with MEC in combination with (oral formulations only) dexamethasone and a 5-HT3 antagonist is effective in preventing More opens in new window

H
harrison, Michelle Date: 10/22/2012
Comment:
I believe aprepitant should be covered for chemotherapy agents classified as moderate risk for More opens in new window
h
Harvey, R Donald Organization: Winship Cancer Institute of Emory University
Date: 10/19/2012
Comment:
I encourage CMS to add moderately-emetogenic chemotherapy regimens to the National Coverage Determination for aprepitant. The use of oral aprepitant with moderately-emetogenic chemotherapy (MEC) in combination with (oral formulations only) More opens in new window
h
Hass, Deborah Title: Assistant Professor
Organization: Midwestern University Chicago College of Pharmacy
Date: 10/22/2012
Comment:
Please approve reimbursement on the use of oral aprepitant for moderately emetogenic chemotherapy in combination with dexamethasone and a 5-HT3 antagonist. Oncolgy patients receiving moderately emetogenic chemotherapy can be prevented from More opens in new window
Page 1 of 3
FirstPrev123NextLast
13